Legend Biotech Corp (LEGN) Equity Average (2020 - 2024)
Legend Biotech (LEGN) has disclosed Equity Average for 5 consecutive years, with $1.1 billion as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Equity Average rose 14.84% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2024, up 14.84%, and an annual FY2024 reading of $1.1 billion, up 14.84% over the prior year.
- Equity Average was $1.1 billion for Q4 2024 at Legend Biotech, up from $997.8 million in the prior quarter.
- Across five years, Equity Average topped out at $1.1 billion in Q4 2024 and bottomed at $374.5 million in Q4 2020.
- Average Equity Average over 5 years is $791.1 million, with a median of $755.1 million recorded in 2022.
- The sharpest move saw Equity Average surged 82.05% in 2021, then increased 10.75% in 2022.
- Year by year, Equity Average stood at $374.5 million in 2020, then soared by 82.05% to $681.9 million in 2021, then rose by 10.75% to $755.1 million in 2022, then soared by 32.14% to $997.8 million in 2023, then increased by 14.84% to $1.1 billion in 2024.
- Business Quant data shows Equity Average for LEGN at $1.1 billion in Q4 2024, $997.8 million in Q4 2023, and $755.1 million in Q4 2022.